10x Genomics Stock Probability of Future Stock Price Finishing Under 12.60
| TXG Stock | USD 16.15 0.28 1.76% |
10X |
10X Genomics Target Price Odds to finish below 12.60
The tendency of 10X Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 12.60 or more in 90 days |
| 16.15 | 90 days | 12.60 | about 5.45 |
Based on a normal probability distribution, the odds of 10X Genomics to drop to $ 12.60 or more in 90 days from now is about 5.45 (This 10X Genomics probability density function shows the probability of 10X Stock to fall within a particular range of prices over 90 days) . Probability of 10X Genomics price to stay between $ 12.60 and its current price of $16.15 at the end of the 90-day period is about 26.57 .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.3 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, 10X Genomics will likely underperform. Additionally 10X Genomics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. 10X Genomics Price Density |
| Price |
Predictive Modules for 10X Genomics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as 10X Genomics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of 10X Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
10X Genomics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. 10X Genomics is not an exception. The market had few large corrections towards the 10X Genomics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold 10X Genomics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of 10X Genomics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.5 | |
β | Beta against Dow Jones | 1.30 | |
σ | Overall volatility | 3.13 | |
Ir | Information ratio | -0.1 |
10X Genomics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of 10X Genomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for 10X Genomics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| 10X Genomics generated a negative expected return over the last 90 days | |
| 10X Genomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 618.73 M. Reported Net Loss for the year was (255.1 M) with profit before taxes, overhead, and interest of 396.02 M. | |
| 10X Genomics has about 499.73 M in cash with (15.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: 46,029 Shares in 10x Genomics, Inc. Purchased by Weiss Asset Management LP - MarketBeat |
10X Genomics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of 10X Stock often depends not only on the future outlook of the current and potential 10X Genomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. 10X Genomics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 117.2 M | |
| Cash And Short Term Investments | 388.7 M |
10X Genomics Technical Analysis
10X Genomics' future price can be derived by breaking down and analyzing its technical indicators over time. 10X Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of 10X Genomics. In general, you should focus on analyzing 10X Stock price patterns and their correlations with different microeconomic environments and drivers.
10X Genomics Predictive Forecast Models
10X Genomics' time-series forecasting models is one of many 10X Genomics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary 10X Genomics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about 10X Genomics
Checking the ongoing alerts about 10X Genomics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for 10X Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| 10X Genomics generated a negative expected return over the last 90 days | |
| 10X Genomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 618.73 M. Reported Net Loss for the year was (255.1 M) with profit before taxes, overhead, and interest of 396.02 M. | |
| 10X Genomics has about 499.73 M in cash with (15.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: 46,029 Shares in 10x Genomics, Inc. Purchased by Weiss Asset Management LP - MarketBeat |
Check out 10X Genomics Backtesting, 10X Genomics Valuation, 10X Genomics Correlation, 10X Genomics Hype Analysis, 10X Genomics Volatility, 10X Genomics History as well as 10X Genomics Performance. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 5.261 | Quarterly Revenue Growth (0.01) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.